Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Anti-obesity medications
Investigational agents
Obesity
Semaglutide
Tirzepatide
Journal
Obesity Pillars (Online)
ISSN: 2667-3681
Titre abrégé: Obes Pillars
Pays: United States
ID NLM: 9918697364706676
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
11
04
2022
accepted:
11
04
2022
medline:
15
4
2022
pubmed:
15
4
2022
entrez:
22
11
2023
Statut:
epublish
Résumé
This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development. The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership. This CPS describes pharmacokinetic principles applicable to those with obesity, and discusses the efficacy and safety of anti-obesity medications [e.g., phentermine, semaglutide, liraglutide, phentermine/topiramate, naltrexone/bupropion, and orlistat, as well as non-systemic superabsorbent oral hydrogel particles (which is technically classified as a medical device)]. Other medications discussed include setmelanotide, metreleptin, and lisdexamfetamine dimesylate. Data regarding the use of combination anti-obesity pharmacotherapy, as well as use of anti-obesity pharmacotherapy after bariatric surgery are limited; however, published data support such approaches. Finally, this CPS discusses investigational anti-obesity medications, with an emphasis on the mechanisms of action and summary of available clinical trial data regarding tirzepatide. This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is one of a series of OMA CPSs designed to assist clinicians in the care of patients with pre-obesity/obesity.
Sections du résumé
Background
UNASSIGNED
This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development.
Methods
UNASSIGNED
The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership.
Results
UNASSIGNED
This CPS describes pharmacokinetic principles applicable to those with obesity, and discusses the efficacy and safety of anti-obesity medications [e.g., phentermine, semaglutide, liraglutide, phentermine/topiramate, naltrexone/bupropion, and orlistat, as well as non-systemic superabsorbent oral hydrogel particles (which is technically classified as a medical device)]. Other medications discussed include setmelanotide, metreleptin, and lisdexamfetamine dimesylate. Data regarding the use of combination anti-obesity pharmacotherapy, as well as use of anti-obesity pharmacotherapy after bariatric surgery are limited; however, published data support such approaches. Finally, this CPS discusses investigational anti-obesity medications, with an emphasis on the mechanisms of action and summary of available clinical trial data regarding tirzepatide.
Conclusion
UNASSIGNED
This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is one of a series of OMA CPSs designed to assist clinicians in the care of patients with pre-obesity/obesity.
Identifiants
pubmed: 37990711
doi: 10.1016/j.obpill.2022.100018
pii: S2667-3681(22)00009-2
pmc: PMC10662004
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100018Informations de copyright
© 2022 The Authors.
Références
Obesity (Silver Spring). 2011 Dec;19(12):2351-60
pubmed: 21527891
Metab Syndr Relat Disord. 2018 Oct;16(8):390-394
pubmed: 29993319
Diabetes Ther. 2021 Aug;12(8):2133-2147
pubmed: 34268675
Curr Obes Rep. 2017 Jun;6(2):187-194
pubmed: 28455679
Obesity (Silver Spring). 2013 May;21(5):893-9
pubmed: 23520198
Metabolism. 2020 Jul;108:154246
pubmed: 32333937
Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206
pubmed: 35131037
Science. 2021 Jul 2;373(6550):
pubmed: 34210852
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801
pubmed: 20707765
N Engl J Med. 2021 Aug 5;385(6):503-515
pubmed: 34170647
Lancet Diabetes Endocrinol. 2019 May;7(5):356-367
pubmed: 30833170
Curr Med Res Opin. 2017 Feb;33(2):225-229
pubmed: 27817208
Lancet. 2010 Aug 21;376(9741):595-605
pubmed: 20673995
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Am J Cardiol. 2014 Jan 1;113(1):76-83
pubmed: 24188894
N Engl J Med. 2010 Sep 2;363(10):905-17
pubmed: 20818901
Cell Rep Med. 2021 May 18;2(5):100284
pubmed: 34095885
Obes Rev. 2006 Nov;7(4):323-31
pubmed: 17038126
Minerva Urol Nefrol. 2018 Aug;70(4):393-400
pubmed: 29856171
Drugs Today (Barc). 2003 Jul;39(7):551-7
pubmed: 12973403
Eye (Lond). 2020 Jan;34(1):12-28
pubmed: 31595027
Diabetes Obes Metab. 2017 Dec;19(12):1762-1772
pubmed: 28573777
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211051919
pubmed: 34663102
Arch Surg. 1976 Mar;111(3):229-33
pubmed: 816331
Nat Med. 2015 Jan;21(1):27-36
pubmed: 25485909
Endocr Pract. 2013 May-Jun;19(3):536-57
pubmed: 23816937
J Clin Lipidol. 2013 Jul-Aug;7(4):304-83
pubmed: 23890517
Nephron. 1977;19(1):12-8
pubmed: 331128
Int J Obes (Lond). 2012 Nov;36(11):1421-7
pubmed: 22184061
Med Clin North Am. 2018 Jan;102(1):135-148
pubmed: 29156182
Hum Vaccin Immunother. 2014;10(4):887-95
pubmed: 24365968
Food Funct. 2021 Jul 21;12(14):6214-6225
pubmed: 34105579
Obes Res. 2004 Aug;12(8):1197-211
pubmed: 15340100
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Peptides. 2018 Feb;100:36-41
pubmed: 29412829
Horm Res Paediatr. 2019;91(2):128-136
pubmed: 30884480
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
Obesity (Silver Spring). 2018 Jan;26(1):70-80
pubmed: 29165885
Can Med Assoc J. 1962 Jul 7;87:29-31
pubmed: 14463177
Curr Opin Lipidol. 2009 Dec;20(6):467-76
pubmed: 19779335
Arch Ophthalmol. 1998 Jul;116(7):874-86
pubmed: 9682700
Diabetes Care. 2017 May;40(5):632-639
pubmed: 28289041
Obesity (Silver Spring). 2014 Apr;22(4):1042-9
pubmed: 24227660
Curr Obes Rep. 2017 Sep;6(3):253-265
pubmed: 28780756
ACS Chem Biol. 2016 Feb 19;11(2):324-8
pubmed: 26727558
N Engl J Med. 2019 Aug 29;381(9):841-851
pubmed: 31185157
Am J Cardiol. 2012 Nov 6;110(9 Suppl):4B-12B
pubmed: 23062567
Diabetes Care. 2020 Oct;43(10):2528-2536
pubmed: 32816874
Curr Diab Rep. 2013 Apr;13(2):245-51
pubmed: 23354680
Br J Pharmacol. 2022 Feb;179(4):557-570
pubmed: 34323288
Metabolism. 2019 Jul;96:46-55
pubmed: 31029770
Yonsei Med J. 2006 Oct 31;47(5):614-25
pubmed: 17066505
Biochimie. 2022 Apr;195:19-26
pubmed: 35045335
Neuroendocrinology. 2011;94(4):291-301
pubmed: 21893952
Clinics (Sao Paulo). 2009;64(7):699-706
pubmed: 19606248
Nat Rev Drug Discov. 2022 Mar;21(3):201-223
pubmed: 34815532
BMJ. 1992 Mar 14;304(6828):713
pubmed: 1571657
J Clin Endocrinol Metab. 2007 May;92(5):1754-7
pubmed: 17341568
Metabolism. 2019 Jul;96:83-91
pubmed: 30902750
Life (Basel). 2021 Dec 25;12(1):
pubmed: 35054422
J Psychopharmacol. 2017 Nov;31(11):1503-1508
pubmed: 29132230
Am J Kidney Dis. 2006 Oct;48(4):555-63
pubmed: 16997051
Cancer Lett. 2021 Feb 28;499:5-13
pubmed: 33264641
Diabetes Metab Syndr Obes. 2017 Jun 10;10:223-234
pubmed: 28652791
Obesity (Silver Spring). 2019 Feb;27(2):205-216
pubmed: 30421844
FASEB J. 2021 May;35(5):e21534
pubmed: 33817830
Compr Ther. 1992 Feb;18(2):20-4
pubmed: 1547598
Am J Clin Nutr. 2021 Feb 2;113(2):314-323
pubmed: 33471039
Expert Opin Pharmacother. 2020 Feb;21(2):167-172
pubmed: 31762335
Am J Clin Nutr. 2012 Feb;95(2):297-308
pubmed: 22158731
Diabetes Metab. 2018 Feb;44(1):4-14
pubmed: 29217386
South Med J. 1990 Apr;83(4):435-40
pubmed: 2181692
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
J Clin Lipidol. 2016 Jan-Feb;10(1):33-57
pubmed: 26892120
Diabetes Care. 2019 Jan;42(Suppl 1):S81-S89
pubmed: 30559234
Clin Exp Vaccine Res. 2014 Jan;3(1):37-41
pubmed: 24427761
Nat Rev Endocrinol. 2020 Nov;16(11):654-667
pubmed: 32764725
Obesity (Silver Spring). 2020 Jun;28(6):1023-1030
pubmed: 32441476
Obesity (Silver Spring). 2013 May;21(5):935-43
pubmed: 23408728
Obesity (Silver Spring). 2019 Apr;27(4):591-602
pubmed: 30900410
Obesity (Silver Spring). 2021 May;29(5):829-836
pubmed: 33818009
Acta Diabetol. 2015 Aug;52(4):649-62
pubmed: 25585592
Life Sci. 2022 Jan 1;288:120188
pubmed: 34861287
Arch Pharm Res. 2019 May;42(5):383-392
pubmed: 30835074
Endocrinol Metab (Seoul). 2021 Feb;36(1):22-29
pubmed: 33677922
Diabetes Metab Syndr Obes. 2019 May 27;12:743-759
pubmed: 31213865
Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1429-45
pubmed: 19900026
Lancet. 2021 Jul 10;398(10295):143-155
pubmed: 34186022
Expert Rev Cardiovasc Ther. 2011 Mar;9(3):265-77
pubmed: 21438803
J Med Chem. 2021 Aug 12;64(15):11183-11194
pubmed: 34288673
Curr Treat Options Cardiovasc Med. 2007 Aug;9(4):259-71
pubmed: 17761111
Am Fam Physician. 1976 Jan;13(1):98-104
pubmed: 1251792
West J Med. 1980 May;132(5):430-9
pubmed: 6992462
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32459834
Braz J Med Biol Res. 2016 Nov 21;49(12):e5826
pubmed: 27878229
Surg Obes Relat Dis. 2018 Jan;14(1):93-98
pubmed: 29287757
J Biol Chem. 2020 Feb 14;295(7):1926-1942
pubmed: 31914415
Obes Surg. 2019 Apr;29(4):1343-1351
pubmed: 30684171
J Clin Lipidol. 2012 Sep-Oct;6(5):413-26
pubmed: 23009777
Diabetes Obes Metab. 2015 Nov;17(11):1021-32
pubmed: 26040215
Expert Rev Cardiovasc Ther. 2006 Nov;4(6):871-95
pubmed: 17173503
Case Rep Gastroenterol. 2015 May 08;9(2):152-5
pubmed: 26078734
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023
pubmed: 24239920
Am J Prev Cardiol. 2021 Jan 23;5:100149
pubmed: 34327491
Cells. 2019 Jul 30;8(8):
pubmed: 31366145
Mol Cell Biol. 2014 Oct 1;34(19):3618-29
pubmed: 25047836
Int J Obes (Lond). 2009 Aug;33(8):857-65
pubmed: 19564877
Int J Obes (Lond). 2016 Aug;40(8):1310-9
pubmed: 27005405
Int J Obes Relat Metab Disord. 2002 Feb;26(2):262-73
pubmed: 11850760
JAMA. 2021 Apr 13;325(14):1414-1425
pubmed: 33755728
BMC Obes. 2017 Feb 21;4:9
pubmed: 28239482
Drugs. 2018 Feb;78(2):163-201
pubmed: 29264783
Br J Clin Pharmacol. 2016 Mar;81(3):412-9
pubmed: 26174744
Indian J Med Res. 2019 Apr;149(4):544-547
pubmed: 31411179
Obesity (Silver Spring). 2020 May;28(5):870-881
pubmed: 32187881
Diabetes Care. 2019 Jun;42(6):1075-1080
pubmed: 31010875
Diabetes Obes Metab. 2019 Mar;21(3):454-466
pubmed: 30226298
Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29959-29967
pubmed: 33177239
Int J Obes (Lond). 2014 Feb;38(2):292-8
pubmed: 23736363
Molecules. 2018 Jul 14;23(7):
pubmed: 30011904
Obesity (Silver Spring). 2020 Jun;28(6):1050-1061
pubmed: 32441473
Surg Obes Relat Dis. 2016 Mar-Apr;12(3):468-495
pubmed: 27050404
Am J Physiol Renal Physiol. 2015 Aug 15;309(4):F273-9
pubmed: 26041447
Curr Genomics. 2018 Nov;19(7):630-666
pubmed: 30386174
J Clin Endocrinol Metab. 2013 Nov;98(11):4391-9
pubmed: 24057293
Ann Plast Surg. 2018 Oct;81(4):503-507
pubmed: 30204622
Obesity (Silver Spring). 2013 Jan;21(1):8-24
pubmed: 23401272
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62
pubmed: 25590212
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21
pubmed: 29364588
Diabetes. 2021 Sep;70(9):1956-1961
pubmed: 34176783
Obes Rev. 2014 Jul;15(7):578-86
pubmed: 24751192
Cell Physiol Biochem. 2017;42(3):1165-1176
pubmed: 28668964
Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):44-7
pubmed: 14737744
Mayo Clin Proc. 2017 May;92(5):774-796
pubmed: 28325505
Curr Atheroscler Rep. 2014 May;16(5):409
pubmed: 24659222
Diabetes. 2020 Apr;69(4):559-566
pubmed: 32198197
Lancet. 2021 Mar 13;397(10278):971-984
pubmed: 33667417
Obesity (Silver Spring). 2013 Nov;21(11):2163-71
pubmed: 24136928
Obstet Gynecol. 2013 Jan;121(1):213-7
pubmed: 23262963
Asian J Androl. 2014 Mar-Apr;16(2):223-31
pubmed: 24407187
Peptides. 2016 Mar;77:28-37
pubmed: 26344355
Curr Med Res Opin. 2009 Mar;25(3):671-81
pubmed: 19232040
Epilepsia. 2012 Sep;53 Suppl 4:127-38
pubmed: 22946730
Lancet. 2021 Jul 17;398(10296):262-276
pubmed: 34216571
Diabetes Care. 2016 Jun;39(6):893-901
pubmed: 27222547
Front Endocrinol (Lausanne). 2021 Mar 29;12:645566
pubmed: 33854484
Histol Histopathol. 2020 Aug;35(8):801-809
pubmed: 31951010
J Clin Lipidol. 2016 Jan-Feb;10(1 Suppl):S1-43
pubmed: 26891998
Front Physiol. 2015 Feb 10;6:36
pubmed: 25713540
N Engl J Med. 2001 Mar 29;344(13):984-96
pubmed: 11274626
Biomed Pharmacother. 2018 Dec;108:952-962
pubmed: 30372907
Niger J Surg. 2018 Jul-Dec;24(2):121-124
pubmed: 30283224
Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243
pubmed: 34176426
Diabetologia. 2017 Oct;60(10):1851-1861
pubmed: 28733905
JAMA. 1999 Jan 20;281(3):235-42
pubmed: 9918478
Lancet. 2021 Nov 13;398(10313):1811-1824
pubmed: 34672967
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Diabetes. 2011 Dec;60(12):3103-9
pubmed: 21984584
Peptides. 2020 Mar;125:170196
pubmed: 31706956
Trends Endocrinol Metab. 2020 Jun;31(6):410-421
pubmed: 32396843
JAMA Netw Open. 2021 Jan 4;4(1):e2033457
pubmed: 33439265
J Fam Pract. 2018 Aug;67(8 suppl):S43-S48
pubmed: 30137053
Ren Fail. 2012;34(10):1348-54
pubmed: 23013150
J Clin Med. 2019 Dec 05;8(12):
pubmed: 31817511
Drugs Today (Barc). 2011 Dec;47(12):903-14
pubmed: 22348915
Sci Transl Med. 2017 Oct 18;9(412):
pubmed: 29046435
JAMA. 2022 Jan 11;327(2):138-150
pubmed: 35015037
Clin Pharmacokinet. 2000 Sep;39(3):215-31
pubmed: 11020136
Obes Sci Pract. 2019 Jun 25;5(4):376-382
pubmed: 31452922
Obesity (Silver Spring). 2015 Apr;23 Suppl 1:S4-7
pubmed: 25900871
Open Biol. 2021 Jul;11(7):210080
pubmed: 34315274
PLoS One. 2016 Aug 09;11(8):e0160212
pubmed: 27504979
J Cell Physiol. 2017 Jan;232(1):61-8
pubmed: 27279601
Am J Ther. 2007 Nov-Dec;14(6):567-80
pubmed: 18090882
Curr Diab Rep. 2019 Dec 4;19(12):156
pubmed: 31802258
Int J Obes (Lond). 2020 Sep;44(9):1859-1871
pubmed: 32015474
JAMA. 2021 Apr 13;325(14):1403-1413
pubmed: 33625476
Br J Clin Pharmacol. 2005 Nov;60(5):578-9
pubmed: 16236051
Diabetes Ther. 2021 Jan;12(1):143-157
pubmed: 33325008
Surg Obes Relat Dis. 2017 Mar;13(3):491-500
pubmed: 27986587
JAMA. 2022 Feb 8;327(6):534-545
pubmed: 35133415
Curr Obes Rep. 2018 Jun;7(2):147-161
pubmed: 29504049
Lancet. 2021 Aug 14;398(10300):583-598
pubmed: 34370970
Arch Intern Med. 2001 Aug 13-27;161(15):1814-24
pubmed: 11493122
Yakugaku Zasshi. 2019;139(11):1479-1483
pubmed: 31685745
Nat Rev Drug Discov. 2016 Sep;15(9):639-660
pubmed: 27256476
Am Heart J. 2020 Nov;229:61-69
pubmed: 32916609
Neurol India. 2005 Mar;53(1):108-9
pubmed: 15805668
J Obes Metab Syndr. 2021 Sep 30;30(3):196-208
pubmed: 34518444
Obes Rev. 2021 Mar;22(3):e13170
pubmed: 33258543
Peptides. 2020 Mar;125:170201
pubmed: 31751656